Abbott Laboratories
ABT: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$592.00 | Fckdzhd | Ghcknqj |
Abbott Pushes Forward on Renewed Demand for COVID-19 Tests; Raising Our Fair Value Estimate
Business Strategy and Outlook
Since 2013, Abbott has continued to improve the profitability of its segments: nutritionals, devices, diagnostics, and established pharmaceuticals. Although the company has made progress over the last eight years, it still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.